Whoop Raises $575 Million, Tripling Valuation to $10 Billion

WHOOP's $575 million Series G round, which closed at a $10.1 billion valuation, is the clearest signal yet that institutional money has decided health data subscriptions are worth treating like a platform business. The Boston-based company's valuation nearly tripled from the $3.6 billion it commanded at its August 2021 Series F, a jump that reflects not just growth expectations but a specific thesis about who pays for wearable health data, and how much they will pay for it.

The round was led by Collaborative Fund and attracted a strategically telling mix of capital. Sovereign wealth funds Qatar Investment Authority and Mubadala Investment Company joined alongside Macquarie Capital, IVP, Foundry, and Bullhound Capital. The more consequential names, however, are Abbott and Mayo Clinic. Their presence signals that investors are not simply betting on a fitness gadget; they are betting that WHOOP's continuous biometric data pipeline becomes a layer in clinical and insurance workflows, not just a consumer wellness accessory. Other participants include 2PointZero Group, Glade Brook, B-Flexion, Accomplice, Affinity Partners, and Promus Ventures.

The cultural validation column is equally crowded. Cristiano Ronaldo, LeBron James, golfer Rory McIlroy, NBA veteran Reggie Miller, cyclist Mathieu van der Poel, soccer players Virgil van Dijk and Shane Lowry, pop musician Niall Horan, and influencer Karen Wazen each joined as individual investors, extending WHOOP's reach across sports and entertainment audiences in a way no ad campaign could replicate.

What investors are actually underwriting is a subscription architecture that has grown more ambitious with each hardware generation. WHOOP no longer sells devices outright. Its current membership tiers, branded One, Peak, and Life, run from $199 to $359 annually and bundle hardware with software access and AI-coaching features. The memberships are now HSA- and FSA-eligible in the United States, reducing the effective cost for health-conscious consumers while positioning WHOOP alongside medical expenditures in household budgets. The company's enterprise product, WHOOP Unite, targets corporate wellness programs and healthcare organizations, creating a B2B revenue stream that complements the consumer side and is precisely the kind of recurring, scalable revenue Abbott and Mayo Clinic would want access to.

The risks are real and, in at least one case, already documented. In 2025, WHOOP received an FDA warning letter over its blood pressure insight feature, which regulators found had been marketed with language, including the phrase "medical-grade health and performance insights," that implied clinical device status without the corresponding clearance. The episode crystallized a tension that sits at the heart of every health-data company: the more medically useful the claims, the more regulatory exposure the product carries. WHOOP ultimately pulled the feature, but the warning letter drew a clear line between wellness insights and clinical diagnostics, a line that will define how far the platform can expand into the higher-margin territory Abbott and Mayo Clinic occupy.

Competition from Apple Watch, Oura Ring, and Garmin devices also constrains pricing power, particularly as Apple continues integrating recovery and sleep metrics that overlap directly with WHOOP's core value proposition. The screenless form factor that distinguishes WHOOP appeals to a specific, committed user, but the addressable market narrows whenever rivals add features without requiring a separate subscription.

The IPO question is not hypothetical. CEO and founder Will Ahmed told Bloomberg in November 2025 that he was considering going public, and a $10.1 billion valuation at the Series G stage is itself a statement of intent: at this price, venture investors need a public-market exit to generate returns. Whether the health data business model, subscriptions plus enterprise plus medical-adjacent insights, can sustain that valuation under quarterly earnings scrutiny is the test that no amount of celebrity capital can answer in advance.